Lynn Dressler

Document Actions

Select Publications

Ten select publications out of a total of 78 publications. No patents.

  1. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellsi MJ, Berry D. HER2  and Benefit from Paclitaxel Chemotherapy for Node Positive Breast Cancer. New England Journal of Medicine. 357 (15):1496-1506., 2007.
  2. Dressler LG. Control and Use of Banked Human Specimens in Research. Biospecimen “Ownership” Counterpoint.  Journal of Cancer Epidemiology, Prevention and Biomarkers. 16(2). 190-191. January, 2007.
  3. Dressler LG and Juengst E. Thresholds and Boundaries in the Disclosure of Individual Genetic Research Results.  American Journal of Bioethics. Nov-Dec; 6(6):18-20. 2006.
  4. Carey L,  Perou C, Livasy C, Dressler L, Conway-Dorsey K, Karaca G, Cowan D, Torester M, Tse C, Edmiston S, Deming S, Geradts J, Cheang M, Nielson T, Moorman P, Earp HS, and R Millikan. The Poor Basal-like Breast Cancer Subtype is Over-represented in Young African-American Women   JAMA 2006; 295:2492-2502.
  5. Dressler LG, Berry DA, Broadwater G, et al. HER2 by Fluorescent in Situ Hybridization (FISH) Compared to Immunohistochemistry Shows Similar Prediction for Outcome Following Dose-Intense Adjuvant Doxorubicin Therapy in Breast Cancer: The CALGB Experience.  J. Clinical Oncology. 2005. July 01. 23:4287-4297.
  6. Dressler, Lynn. Human Specimens, Cancer Research and Drug Development:  How Science Policy can Promote Progress and Protect Research Participants. Invited Background Paper.  National Cancer Advisory Board of the Institutes of Medicine (IOM).  March, 2005. Available at: http://www.iom.edu/Object.File/Master/26/207/IOM_fnl.pdf
  7. Dressler LG and Thor A. HER2 testing. Laboratory, Technical and Clinical Issues. Int’l J of Breast Disease. 11:77-87. 2000.
  8. Dressler LG, Geradts J, Burroughs M, Cowan D, Millikan RC and Newman B.  Policy guidelines for the utilization of formalin- fixed, paraffin-embedded tissue sections. The UNC SPORE experience. Breast Cancer Research and Treatment. 58(1). 31-39. 1999.
  9. Dressler LG.  Genetic Testing for the BRCA1 Gene and the Need for Protection from Discrimination: an Evolving Legislative and Social Issue. Int. J of Breast Disease. 10(1,2): 127-135. 1998.
  10. Dressler LG, Eudey L, Gray R, Tormey D, Gilchrist K, McGuire WL, Clark G, Osborne CKO, Mansour E, Abeloff M.  Prognostic potential of DNA flow cytometry measurements in node negative breast cancer patients: Preliminary analysis of an intergroup study (INT0076).  Journal of the National Cancer Institute 167-172, 1992.